Chronic inflammation is causally associated with the development of many cancers, often resulting in a "cytokine storm" that facilitates tumor progression. Therapy could be directed to appropriately "quiet the storm" while beneficial for the tumor, could result in negative effects on the host. The NF-?B family of transcription factors is required for the generation of the 'cytokine storm'. Malignant melanoma, the most deadly type of skin cancer, provides a uniquely valuable model for testing the balance between immunity and intrinsic resistance in tumor growth. We have demonstrated that inhibiting IKK2, the major kinase that activates the canonical NF-?B pathway, in melanoma tumor bearing mice results in reduced tumor growth. Moreover, targeted deletion of IKK2 in melanocytes prevents mutant Ras-mediated melanoma tumor formation in mice that have lost the tumor suppressors INK4a/ARF. Current therapies for disseminated melanoma are largely ineffective. Small molecule inhibitors of IKK2, by directly blocking the canonical NF-?B pathway, may be effective in the clinic for metastatic melanoma. Aurora Kinase (Aurk) inhibitors readily block cell cycle progression in tumor cells and also indirectly inhibit NF-kB, while inhibitors of NF-?B inhibit Aurk and target many types of tumor cells for apoptosis. Clinical trials are currently ongoing using small molecule inhibitors of IKK2 and AurK for other solid tumors and haematological malignancies. Melanoma might be highly responsive to inhibitors to these two kinases, but before initiating such studies, potentially harmful effects of inhibiting the NF-kB pathway on the host immune response require clarification. In this proposal we will test the hypothesis that the benefits of targeting IKK2 or AurkA will outweigh the risks for patients with aggressive metastatic melanoma and constitutive activation of these pathways. We also hypothesize that inhibiting NF-kB with IKK2 or AurKA inhibitors will boost the immune response to the tumor by shifting leukocyte profile in the tumor microenvironment from one that is pro-tumorigenic (M2, N2, Th2) to one that is anti-tumorigenic (M1/N1/Th1). Moreover, there are documented cases of tumors developing resistance to Aurk inhibitors and in these instances we hypothesize that resistance to therapy with Aurk or IKK inhibitors will be associated with mutations in Aurk or kinases in the IKK pathway. There are three specific aims: 1) To determine whether treatment with IKK2 or AurkA inhibitors results in loss of intrinsic immunity to "silent" tumors. 2) To characterize the effects of systemic inhibition of IKK2 versus AurkA on the leukocytes infiltrate and cytokine profile in the tumor microenvironment;3) To characterize the mechanism by which melanoma tumors sensitive to IKK2 or Aurk inhibitors become growth arrested then later resistant to these inhibitors. Insights from this pre-clinical work should allow appropriate design of clinical trials to test the efficacy of IKK2 and Aurk inhibitors for melanoma therapy. The ultimate goal of this work is to develop insight for improved individualized therapy for malignant melanoma patients to increase survival.

Public Health Relevance

Using mouse models, we will 1)evaluate the benefits and risks of targeting IKK2 and/or Aurks in patients with aggressive melanoma;2) evaluate the short and long term effects on the immune response to tumor when these kinases are inhibited;3) determine the mechanisms for development of resistance to these inhibitors

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA116021-09
Application #
8403827
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Arya, Suresh
Project Start
2005-08-19
Project End
2014-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
9
Fiscal Year
2013
Total Cost
$308,657
Indirect Cost
$110,800
Name
Vanderbilt University Medical Center
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Vilgelm, Anna E; Pawlikowski, Jeff S; Liu, Yan et al. (2015) Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res 75:181-93
Ciombor, Kristen K; Feng, Yang; Benson 3rd, Al Bowen et al. (2014) Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs 32:1017-27
Davis, Tyler A; Vilgelm, Anna E; Richmond, Ann et al. (2013) Preparation of (-)-Nutlin-3 using enantioselective organocatalysis at decagram scale. J Org Chem 78:10605-16
Liu, Yan; Hawkins, Oriana E; Su, Yingjun et al. (2013) Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-?B impairs this drug-induced senescence. EMBO Mol Med 5:149-66
Raman, Dayanidhi; Sobolik-Delmaire, Tammy; Richmond, Ann (2011) Chemokines in health and disease. Exp Cell Res 317:575-89
Richmond, Ann (2011) Chemokine research moves on. Exp Cell Res 317:553-5
Lazennec, Gwendal; Richmond, Ann (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16:133-44
Wang, Dingzhi; Dubois, Raymond N; Richmond, Ann (2009) The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol 9:688-96
Richmond, Ann; Yang, Jinming; Su, Yingjun (2009) The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res 22:175-86
Yang, Li; Huang, Jianhua; Ren, Xiubao et al. (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23-35

Showing the most recent 10 out of 20 publications